Trinitas Capital: Funding, Team & Investors

Trinitas Capital Management operates as a credit-focused investment management firm, specializing in senior secured bank loans. Its core strategy centers on issuing and managing collateralized loan obligations (CLOs) and tailored separate accounts. The firm’s capabilities encompass deep expertise in bank loan investing, active portfolio management, credit analysis, and CLO deal structuring and compliance.

Established in 2015, Trinitas Capital Management was shaped by leaders Gibran Mahmud, CEO and CIO, and Philip Braner, COO. Both bring extensive structured finance backgrounds from prior roles, notably at Highland Capital Management. This collective experience provided the foundational insight for building a firm dedicated to advanced credit investment strategies and CLO platforms.

Trinitas Capital Management serves institutional investors seeking focused credit market exposure through its structured finance offerings. The company’s vision emphasizes expanding its sophisticated CLO issuance platform and growing tailored separate accounts, aspiring to deliver specialized credit solutions amidst the evolving financial landscape.

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
May 22, 2021	HiberCell	$97.4M Debt / Series B	—	ARCH Venture Partners, Bristol Myers Squibb, Hercules Capital, Huizenga Capital Management, Magnetic Ventures, Rene Mora, Mount Sinai Innovation Partners, Tekla Capital Management
Apr 1, 2019	Vividion Therapeutics	$82.0M Series B	Jakob Loven	ARCH Venture Partners, Canaan Partners, Cure Ventures, Earlybird Venture Capital, Nextech Invest, VenBio Partners, Versant Ventures, Vivo Capital, Alexandria Venture Investments, Altitude Life Science Ventures, BVF Partners, Cardinal Partners, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Capital
Feb 21, 2018	ORIC Pharmaceuticals	$50.0M Series C	—	EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Kravis Investment Partners, Memorial Sloan Kettering Cancer Center, NS Investment, OrbiMed, Taiho Ventures, The Column Group, Topspin Fund
Sep 1, 2017	Gritstone bio	$93.0M Series B	Judith LI	Aisling Capital, Avoro Ventures, General Atlantic, GV, OrbiMed, The Column Group, Versant Ventures, Alexandria Venture Investments, Clarus Ventures, Frazier Healthcare Partners
Mar 1, 2016	Quanterix	$46.0M Series D	ARCH Venture Partners, Bihua Chen, Trinitas Capital	LUX Capital, David R. Walt, Bain Capital Ventures, Hercules Capital, Tufts University

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
May 22, 2021	HiberCell	$97.4M Debt / Series B	—	ARCH Venture Partners, Bristol Myers Squibb, Hercules Capital, Huizenga Capital Management, Magnetic Ventures, Rene Mora, Mount Sinai Innovation Partners, Tekla Capital Management
Apr 1, 2019	Vividion Therapeutics	$82.0M Series B	Jakob Loven	ARCH Venture Partners, Canaan Partners, Cure Ventures, Earlybird Venture Capital, Nextech Invest, VenBio Partners, Versant Ventures, Vivo Capital, Alexandria Venture Investments, Altitude Life Science Ventures, BVF Partners, Cardinal Partners, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Capital
Feb 21, 2018	ORIC Pharmaceuticals	$50.0M Series C	—	EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Kravis Investment Partners, Memorial Sloan Kettering Cancer Center, NS Investment, OrbiMed, Taiho Ventures, The Column Group, Topspin Fund
Sep 1, 2017	Gritstone bio	$93.0M Series B	Judith LI	Aisling Capital, Avoro Ventures, General Atlantic, GV, OrbiMed, The Column Group, Versant Ventures, Alexandria Venture Investments, Clarus Ventures, Frazier Healthcare Partners
Mar 1, 2016	Quanterix	$46.0M Series D	ARCH Venture Partners, Bihua Chen, Trinitas Capital	LUX Capital, David R. Walt, Bain Capital Ventures, Hercules Capital, Tufts University

Trinitas Capital

About

Investment Activity

Investments Made

Financial History

Investment Activity

Investments Made